Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.
Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, Umutlu L, Coman C, Ahrends R, Sickmann A, Löffek S, Livingstone E, Ugurel S, Zimmer L, Gunzer M, Schadendorf D, Totzeck M, Rassaf T. Michel L, et al. Among authors: odersky a. Eur Heart J. 2022 Jan 31;43(4):316-329. doi: 10.1093/eurheartj/ehab430. Eur Heart J. 2022. PMID: 34389849
Superiority of focused ion beam-scanning electron microscope tomography of cardiomyocytes over standard 2D analyses highlighted by unmasking mitochondrial heterogeneity.
Heinen-Weiler J, Hasenberg M, Heisler M, Settelmeier S, Beerlage AL, Doepper H, Walkenfort B, Odersky A, Luedike P, Winterhager E, Rassaf T, Hendgen-Cotta UB. Heinen-Weiler J, et al. Among authors: odersky a. J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):933-954. doi: 10.1002/jcsm.12742. Epub 2021 Jun 13. J Cachexia Sarcopenia Muscle. 2021. PMID: 34120411 Free PMC article.
Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart.
Korste S, Settelmeier S, Michel L, Odersky A, Stock P, Reyes F, Haj-Yehia E, Anker MS, Grüneboom A, Hendgen-Cotta UB, Rassaf T, Totzeck M. Korste S, et al. Among authors: odersky a. Int J Mol Sci. 2023 Mar 23;24(7):6052. doi: 10.3390/ijms24076052. Int J Mol Sci. 2023. PMID: 37047026 Free PMC article.
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Sadowski N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH. Henssen A, et al. Among authors: odersky a. Clin Cancer Res. 2016 May 15;22(10):2470-81. doi: 10.1158/1078-0432.CCR-15-1449. Epub 2015 Dec 2. Clin Cancer Res. 2016. PMID: 26631615
Targeting tachykinin receptors in neuroblastoma.
Henssen AG, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, Speleman F, Schäfers S, De Preter K, Astrahanseff K, Struck J, Schramm A, Eggert A, Bergmann A, Schulte JH. Henssen AG, et al. Among authors: odersky a. Oncotarget. 2017 Jan 3;8(1):430-443. doi: 10.18632/oncotarget.13440. Oncotarget. 2017. PMID: 27888795 Free PMC article.
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH. Heukamp LC, et al. Among authors: odersky a. Sci Transl Med. 2012 Jul 4;4(141):141ra91. doi: 10.1126/scitranslmed.3003967. Sci Transl Med. 2012. PMID: 22764207
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.
Althoff K, Beckers A, Odersky A, Mestdagh P, Köster J, Bray IM, Bryan K, Vandesompele J, Speleman F, Stallings RL, Schramm A, Eggert A, Sprüssel A, Schulte JH. Althoff K, et al. Among authors: odersky a. Int J Cancer. 2013 Sep 1;133(5):1064-73. doi: 10.1002/ijc.28091. Epub 2013 Mar 7. Int J Cancer. 2013. PMID: 23400681 Free article.
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH. Henssen A, et al. Among authors: odersky a. Oncotarget. 2013 Nov;4(11):2080-95. doi: 10.18632/oncotarget.1534. Oncotarget. 2013. PMID: 24231268 Free PMC article.
miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin.
Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, Molenaar JJ, Bohrer A, Knauer S, Speleman F, Epple M, Kozlova D, Yoon S, Baek K, Vandesompele J, Eggert A, Schramm A, Schulte JH. Althoff K, et al. Among authors: odersky a. Int J Cancer. 2015 Mar 15;136(6):1308-20. doi: 10.1002/ijc.29091. Epub 2014 Aug 5. Int J Cancer. 2015. PMID: 25046253 Free article.
20 results